Why Cipla Shares jumped 4% today?

22 Jun 2026 , 02:47 PM

Cipla has come back into focus after Citi reiterated a Buy rating and placed the stock on a 90-day Positive Catalyst Watch, highlighting multiple near-term triggers and a potential earnings recovery phase ahead. The brokerage’s target price of around ₹1,700 implies nearly 25% upside, driven by improving US launches, stable India business performance, and regulatory optionality.

Citi’s Positive View on Cipla: What Changed?

Citi’s upgrade reflects a shift in sentiment around Cipla’s near-term earnings trajectory. After a period of weakness, the brokerage believes the worst may be behind the company, with several catalysts lining up over the next quarters.

Key highlights include:

• US product pipeline improvements
• Domestic business stability
• Regulatory upside potential
• Margin recovery trends
• Attractive valuation vs peers

 

Near-Term US Product Catalysts Driving Growth

One of the most important triggers identified is the revival in Cipla’s US business, which has recently seen pressure.

Upcoming product catalysts include:

• gFlovent approvals (expected from the Goa facility)
• gVentolin launch anticipated in the near term

These launches are expected to:

• Strengthen Cipla’s US portfolio
• Support revenue recovery in the American market
• Improve overall profitability mix

Additionally, Cipla’s specialty positioning is supported by Nintedanib, which holds around 50% market share in the US, reinforcing its niche strength.

India Business Remains a Strong Anchor

Cipla’s India formulations business continues to provide stability, contributing nearly two-thirds of EBITDA.

Key strengths include:

• Continued strength in domestic demand
• Recovery in respiratory portfolio
• Stable earnings contribution despite global volatility

This strong India base provides resilience while the US recovery plays out.

Regulatory Upside: Indore Plant Re-Inspection in Focus

Another important trigger is the upcoming USFDA re-inspection of the Indore facility.

A positive outcome could:

• Unlock additional product approvals
• Improve US pipeline visibility
• Act as a sentiment booster for the stock

Regulatory clarity remains a key near-term watchpoint for investors.

Earnings Outlook: Signs of a Bottoming Phase

Citi believes Cipla’s earnings may have already bottomed out, especially after the impact from gRevlimid-related pressures.

Key takeaways:

• Recent weak quarter likely represents the bottom
• Earnings trajectory expected to improve going forward
• Recovery supported by new launches and stable core business

Valuation: Reasonable vs Pharma Peers

Cipla currently trades at:

• ~25x FY27E earnings
• ~21x FY28E earnings

According to Citi, this valuation is:

• Reasonable relative to Indian pharma peers
• Justified given expected earnings recovery
• Attractive when factoring in upcoming catalysts

Margin Tailwinds and Cost Stability

Cipla may also benefit from improving cost conditions:

• Easing geopolitical pressures could stabilize raw material costs
• Margin recovery potential as product mix improves
• Operational leverage from US launches

Weak Q4 Performance: Already Discounted?

Despite a sharp ~55% decline in profit in the recent quarter, the market appears to have already priced in near-term weakness.

Citi’s view suggests:

• Weak results reflect a temporary trough
• Forward earnings trend is expected to improve
• Investor focus is shifting to FY27–FY28 recovery story

Disclaimer – The stock/s and indices mentioned in this article is discussed solely for informational and educational purposes. It should not be construed as investment advice or a recommendation to buy or sell any securities. Investors should conduct their own research or consult a financial advisor before making any investment decisions. Investments in securities market are subject to market risks. Read all the related documents carefully before investing.